109 related articles for article (PubMed ID: 37384209)
21. Characterization of Adverse Cutaneous Effects in the Setting of Enfortumab Vedotin for Metastatic Urothelial Carcinoma - a Retrospective Review.
Malik R; Xiang DH; Riew GJ; Sanchez-Melendez S; Afvari S; LeBoeuf NR; Nambudiri VE
J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38909660
[No Abstract] [Full Text] [Related]
22. Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus.
Kurokawa M; Naito S; Ito S; Takai S; Kawamura Y; Kaneko H; Kakizaki H; Tsuchiya N
IJU Case Rep; 2020 Sep; 3(5):181-183. PubMed ID: 32914068
[TBL] [Abstract][Full Text] [Related]
23. Refining the subgroup analyses and optimal patient population in the JAVELIN Bladder 100 trial.
Aragon-Ching JB
Transl Androl Urol; 2024 Apr; 13(4):635-638. PubMed ID: 38721289
[No Abstract] [Full Text] [Related]
24. Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer.
Vogl UM; Testi I; De Santis M
Eur Urol Focus; 2024 Apr; ():. PubMed ID: 38582643
[TBL] [Abstract][Full Text] [Related]
25. Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma.
Drake MJ; Birder LA
Eur Urol; 2024 Mar; ():. PubMed ID: 38538426
[No Abstract] [Full Text] [Related]
26. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
[No Abstract] [Full Text] [Related]
27. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Klümper N; Vera-Badillo FE; Eckstein M; Hadaschik B; Grünwald V
Eur Urol; 2024 Apr; ():. PubMed ID: 38599990
[No Abstract] [Full Text] [Related]
28. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Chen DC; AlSaffar H; Graefen H; Perera S; Mazzone E; Perera ML; Lawrentschuk N; Murphy DG
Eur Urol; 2024 Apr; ():. PubMed ID: 38631993
[No Abstract] [Full Text] [Related]
29. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Catalano M; Santoni M; Roviello G
Eur Urol; 2024 May; ():. PubMed ID: 38744633
[No Abstract] [Full Text] [Related]
30. The Future of Front-line Metastatic Bladder Cancer is Platinum-free.
Young M
Eur Urol Focus; 2024 Apr; ():. PubMed ID: 38658299
[TBL] [Abstract][Full Text] [Related]
31. Desquamative extravasation reaction secondary to enfortumab vedotin.
Pulavarty AN; Meehan S; Weed J
JAAD Case Rep; 2024 Apr; 46():15-17. PubMed ID: 38496727
[No Abstract] [Full Text] [Related]
32. SDRIFE and bullous reaction after treatment with enfortumab vedotin plus pembrolizumab: Case series.
Lluch-Galcerá JJ; Manzanares-Oliver N; Martinez-Molina M; Valdivieso L; Boada A; Segura S; Rovira R; Pujol RM; Jaka A
J Dtsch Dermatol Ges; 2024 May; ():. PubMed ID: 38778438
[No Abstract] [Full Text] [Related]
33. Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
Nally E; Young M; Wells C; Fairhead R; Baines K; Cheney-Lowe H; Jackson-Spence F; Powles T
Eur Urol Focus; 2024 Jun; ():. PubMed ID: 38825408
[TBL] [Abstract][Full Text] [Related]
34. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.
Zschäbitz S; Biernath N; Hilser T; Höllein A; Zengerling F; Cascucelli J; Paffenholz P; Seidl D; Lutz C; Schlack K; Kingreen D; Klümper N; Ivanyi P; von Amsberg G; Heers H; Roghmann F; Tauber RL; Cathomas R; Hofer L; Niegisch G; Klee M; Ehrenberg R; Hassler A; Hadaschik BA; Grünwald V; Darr C
Eur Urol Open Sci; 2023 Jul; 53():31-37. PubMed ID: 37441344
[TBL] [Abstract][Full Text] [Related]
35. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
Shafique MA; Haseeb A; Siddiq MA; Mussarat A; Rangwala HS; Mustafa MS
Cancer Manag Res; 2023; 15():699-706. PubMed ID: 37485038
[TBL] [Abstract][Full Text] [Related]
36. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
37. Drug extravasation with Enfortumab vedotin.
Grant CR; de Kouchkovsky D; Kalebasty AR; Mar N
J Oncol Pharm Pract; 2023 Oct; 29(7):1789-1792. PubMed ID: 37401244
[TBL] [Abstract][Full Text] [Related]
38. Upper Tract Urothelial Carcinoma: A Rare Malignancy with Distinct Immuno-Genomic Features in the Era of Precision-Based Therapies.
Evmorfopoulos K; Mitrakas L; Karathanasis A; Zachos I; Tzortzis V; Vlachostergios PJ
Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509415
[TBL] [Abstract][Full Text] [Related]
39. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
[TBL] [Abstract][Full Text] [Related]
40. Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.
Alameddine R; Mallea P; Shahab F; Zakharia Y
Curr Treat Options Oncol; 2023 Sep; 24(9):1167-1182. PubMed ID: 37403009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
